News
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
After initially refusing to suspend Elevidys distribution after two deaths, Sarepta has now given in to the FDA’s request, ...
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.
A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
15h
India Today on MSNChildren's Hospital LA halts use of Sarepta's gene therapy for all patientsChildren's Hospital Los Angeles paused Sarepta's Elevidys gene therapy after FDA flagged safety issues, including deaths in ...
Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators ...
The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results